Prelude Therapeutics Incorporated
PRLD
$3.94
$0.102.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 138.86% | 73.43% | 250.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 138.86% | 73.43% | 250.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 138.86% | 73.43% | 250.00% | -- | -- |
| SG&A Expenses | -21.41% | -22.33% | -20.08% | -8.45% | -3.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.26% | -21.34% | -10.06% | -0.19% | 6.89% |
| Operating Income | 40.82% | 26.09% | 15.51% | 5.11% | -1.80% |
| Income Before Tax | 39.14% | 21.76% | 15.01% | 4.26% | -1.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.14% | 21.76% | 15.01% | 4.26% | -1.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.14% | 21.76% | 15.01% | 4.26% | -1.82% |
| EBIT | 40.82% | 26.09% | 15.51% | 5.11% | -1.80% |
| EBITDA | 41.26% | 26.38% | 15.80% | 5.35% | -1.47% |
| EPS Basic | 40.50% | 22.58% | 17.09% | 9.10% | 10.57% |
| Normalized Basic EPS | 41.48% | 23.56% | 17.09% | 9.10% | 10.56% |
| EPS Diluted | 40.25% | 22.81% | 17.32% | 9.36% | 10.81% |
| Normalized Diluted EPS | 41.48% | 23.56% | 17.09% | 9.10% | 10.56% |
| Average Basic Shares Outstanding | 3.59% | 1.52% | 2.37% | 5.19% | 12.73% |
| Average Diluted Shares Outstanding | 3.59% | 1.52% | 2.37% | 5.19% | 12.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |